pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 25·1 min read
save

Massachusetts biotech workforce rebounds after 2025 decline

Aug 25, 2026·read at STAT ↗Positive

A new report from the Massachusetts Biotechnology Council shows the state’s biopharma employment fell by about 3,600 workers in 2025, marking the first drop since at least 2002.

The workforce total fell to 113,503, a 3.1% decrease from the 2024 level, as industry headwinds and uncertainty over federal research funding weighed on hiring.

Despite the 2025 contraction, analysts say the sector is turning a corner in 2026, with hiring picking up and previously vacant lab spaces beginning to fill.

The rebound is being watched closely by investors and companies, who see the trend as an early indicator of renewed venture capital flow and growth in the Greater Boston biotech hub.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: After a years-long slump, Massachusetts biopharma sector has come roaring back in 2026”

read at STAT ↗
391 words · retrieved Aug 25
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Gene Therapy (AAV)2Oncology2Vaccine

related stories

  • 2d agoFoghorn cuts 40% of workforceBioSpace
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Aug 27STAT+: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and moreSTAT
  • Aug 26STAT+: Key data on a new class of cardio drugs are comingSTAT
  • Aug 25STAT+: Pharmalittle: We’re reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and moreSTAT